Stuart Johnson1, Thomas J Louie2, Dale N Gerding1, Oliver A Cornely3, Scott Chasan-Taber4, David Fitts5, Steven P Gelone5, Colin Broom5, David M Davidson4. 1. Loyola University Medical Center and Hines Veterans Administration Hospital, Chicago, Illinois. 2. University of Calgary, Alberta, Canada. 3. Department of Internal Medicine, Clinical Trials Centre Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Germany. 4. Genzyme, Cambridge, Massachusetts. 5. ViroPharma Incorporated, Exton, Pennsylvania.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) is a common complication of antibiotic therapy that is treated with antibiotics, contributing to ongoing disruption of the colonic microbiota and CDI recurrence. Two multinational trials were conducted to compare the efficacy of tolevamer, a nonantibiotic, toxin-binding polymer, with vancomycin and metronidazole. METHODS:Patients with CDI were randomly assigned in a 2:1:1 ratio to oral tolevamer 9 g (loading dose) followed by 3 g every 8 hours for 14 days, vancomycin 125 mg every 6 hours for 10 days, or metronidazole 375 mg every 6 hours for 10 days. The primary endpoint was clinical success, defined as resolution of diarrhea and absence of severe abdominal discomfort for more than 2 consecutive days including day 10. RESULTS: In a pooled analysis, 563 patients received tolevamer, 289 receivedmetronidazole, and 266 received vancomycin. Clinical success of tolevamer was inferior to both metronidazole and vancomycin (P < .001), and metronidazole was inferior to vancomycin (P = .02; 44.2% [n = 534], 72.7% [n = 278], and 81.1% [n = 259], respectively). Clinical success in patients with severe CDI who received metronidazole was 66.3% compared with vancomycin, which was 78.5%. (P = .059). A post-hoc multivariate analysis that excluded tolevamer found 3 factors that were strongly associated with clinical success: vancomycin treatment, treatment-naive status, and mild or moderate CDI severity. Adverse events were similar among the treatment groups. CONCLUSIONS: Tolevamer was inferior to antibiotic treatment of CDI, and metronidazole was inferior to vancomycin. Trial Registration. clinicaltrials.gov NCT00106509 and NCT00196794. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND:Clostridium difficileinfection (CDI) is a common complication of antibiotic therapy that is treated with antibiotics, contributing to ongoing disruption of the colonic microbiota and CDI recurrence. Two multinational trials were conducted to compare the efficacy of tolevamer, a nonantibiotic, toxin-binding polymer, with vancomycin and metronidazole. METHODS:Patients with CDI were randomly assigned in a 2:1:1 ratio to oral tolevamer 9 g (loading dose) followed by 3 g every 8 hours for 14 days, vancomycin 125 mg every 6 hours for 10 days, or metronidazole 375 mg every 6 hours for 10 days. The primary endpoint was clinical success, defined as resolution of diarrhea and absence of severe abdominal discomfort for more than 2 consecutive days including day 10. RESULTS: In a pooled analysis, 563 patients received tolevamer, 289 received metronidazole, and 266 received vancomycin. Clinical success of tolevamer was inferior to both metronidazole and vancomycin (P < .001), and metronidazole was inferior to vancomycin (P = .02; 44.2% [n = 534], 72.7% [n = 278], and 81.1% [n = 259], respectively). Clinical success in patients with severe CDI who received metronidazole was 66.3% compared with vancomycin, which was 78.5%. (P = .059). A post-hoc multivariate analysis that excluded tolevamer found 3 factors that were strongly associated with clinical success: vancomycin treatment, treatment-naive status, and mild or moderate CDI severity. Adverse events were similar among the treatment groups. CONCLUSIONS:Tolevamer was inferior to antibiotic treatment of CDI, and metronidazole was inferior to vancomycin. Trial Registration. clinicaltrials.gov NCT00106509 and NCT00196794. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Shannon A Novosad; Yi Mu; Lisa G Winston; Helen Johnston; Elizabeth Basiliere; Danyel M Olson; Monica M Farley; Andrew Revis; Lucy Wilson; Rebecca Perlmutter; Stacy M Holzbauer; Tory Whitten; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Valerie L S Ocampo; Corinne M Davis; Marion Kainer; Dale N Gerding; Alice Y Guh Journal: J Gen Intern Med Date: 2019-11-25 Impact factor: 5.128
Authors: Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly Journal: Anaerobe Date: 2015-04-27 Impact factor: 3.331
Authors: Abrar K Thabit; Mawadah H Alsolami; Nojoud A Baghlaf; Raghad M Alsharekh; Hadeel A Almazmumi; Afrah S Alselami; Fatmah A Alsubhi Journal: Infection Date: 2019-08-19 Impact factor: 3.553
Authors: Wan-Jou Shen; Aditi Deshpande; Kirk E Hevener; Bradley T Endres; Kevin W Garey; Kelli L Palmer; Julian G Hurdle Journal: J Antimicrob Chemother Date: 2020-04-01 Impact factor: 5.790
Authors: Philip T Cherian; Xiaoqian Wu; Lei Yang; Jerrod S Scarborough; Aman P Singh; Zahidul A Alam; Richard E Lee; Julian G Hurdle Journal: J Antimicrob Chemother Date: 2015-08-18 Impact factor: 5.790
Authors: Samuel L Aitken; M Jahangir Alam; Mohammed Khaleduzzaman; Mohammed Khaleduzzuman; Seth T Walk; William L Musick; Vy P Pham; Jennifer L Christensen; Robert L Atmar; Yang Xie; Kevin W Garey Journal: Infect Control Hosp Epidemiol Date: 2015-08-20 Impact factor: 3.254